Datwyler maintains strong EBIT profit margin despite sales decline

LootboxPhobia · 2026-02-12T14:03:55+00:00

Datwyler reports sales of CHF 538 million in the second half of 2025, slightly below expectations, but EBIT profit margin reaches 12.6%. The healthcare division performs well, with full-year sales of CHF 1.101 billion and a dividend of CHF 3.20 per share. The company expects future sales and profitability to grow and is undergoing leadership changes. Analysts are optimistic about market reactions.

LootboxPhobia

2026-02-12 14:03:55

Abstract generation in progress

Investing.com – Datwyler reported on Thursday that its sales for the second half of 2025 were 538 million Swiss francs, slightly below expectations, but its profitability exceeded forecasts, with an EBIT margin of 12.6%.

The Swiss industrial components supplier’s healthcare division performed particularly well, achieving 10.6% organic growth in the second half of 2025, while the industrial division recorded a more moderate 1.5% organic growth.

For the full year 2025, Datwyler achieved group sales of 1.101 billion Swiss francs, with an adjusted EBIT margin of 12.4%, up from 12.0% in 2024, indicating improved profitability. The company proposed a dividend of 3.20 Swiss francs per share.

Looking ahead, Datwyler provided a qualitative outlook for 2026, expecting both sales and profitability to grow. The company anticipates the healthcare division will achieve “structural growth,” the automotive division will see “vehicle production remain broadly stable,” and the industrial division will experience “steady demand with selective growth.”

The company also announced several changes to its supervisory board, including the nomination of a new chairman. Mr. Breu, currently CEO of SFS, will be nominated to serve as Datwyler’s chairman, due to leadership age-related transitions.

UBS analysts expect the market to respond positively to these results, highlighting the strong growth in the healthcare division and the continuous improvement in profit margins within this key business area.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.